The Milwaukee Community Clinical Oncology Program is a consortium of twenty physicians, three oncology research nurses and five institution in southeastern Wisconsin whose long term objective is to decrease the morbidity and mortality of cancer by involving the patient resources and personnel of private oncologic practitioners in clinical research. I provides an operational base to extend to the mIlwaukee community cancer control research in areas of early detection, prevention, screening, pre-treatment evaluation, treatment, continuing care and rehabilitation as conducted by the national cooperative groups, university research bases and the National Cancer Institute. It utilizes these innovative research protocols in a network of community physicians, facilities and resources and provides detailed data collection. The formal affiliation between the Milwaukee community and the research bases provides a foundation for an effective cancer control network that is comprehensive, accountable and responsive to the cancer control goals of the National Caner Institute.
Byrd, John C; Rai, Kanti; Peterson, Bercedis L et al. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53 |
Stone, R M; Berg, D T; George, S L et al. (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548-53 |
Hayes, D F; Yamauchi, H; Broadwater, G et al. (2001) Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7:2703-11 |